Overview

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

Status:
Active, not recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeks

Phase:

Phase 3

Details

Lead Sponsor:

Mapi Pharma Ltd.

Treatments:

(T,G)-A-L
Glatiramer Acetate